WT1 Cancer Vaccine
What is WT1 Cancer Vaccine?
In the immune system, dendritic cells (DCs) act like instructors in an army. They use antigens released by cancer cells or pathogens to train inactive cells. Dendritic cells are considered the most potent antigen-presenting cells in the immune system, capable of stimulating and amplifying cell activation, producing a large number of T cells that specifically recognize and attack cancer cells or virus-infected cells.
Reasons to Choose WT1 Vaccine
-
Targeted Treatment : The WT1 vaccine is a treatment method that targets specific cancer markers. The WT1 protein is highly expressed in certain cancer cells, so this vaccine can help the immune system more accurately identify and attack these cancer cells, providing more effective treatment.
-
Fewer Side Effects : Compared to some traditional cancer treatments such as chemotherapy and radiation therapy, vaccine therapy usually has fewer side effects. This means that patients can better tolerate the treatment process, improving their quality of life.
-
Long-term Effects : The WT1 vaccine can stimulate long-lasting immune memory, enabling the immune system to better recognize and attack cancer cells in the future. This can reduce the risk of cancer recurrence, providing long-term protection.
-
Personalized Treatment : The WT1 vaccine is a personalized treatment method that can be customized according to the patient's specific condition. Since each person's cancer is unique, this personalized treatment can better meet the patient's needs and provide more effective treatment plans.
The Process of Administering the WT1 Vaccine
-
Pre-Treatment Examination : Various examinations, such as blood tests and imaging studies, are conducted to determine if the patient is suitable for dendritic cell vaccine therapy.
-
Doctor Consultation : The primary doctor will conduct a consultation with the patient to assess their physical condition and develop an appropriate treatment plan.
-
WT1 Vaccine Administration : The WT1 vaccine is administered via subcutaneous injection into the patient's body. This is done once a month for a total of three times.
Dr. Choi Tat Fai Richard (Surgeon)
-
Bachelor of Medicine and Bachelor of Surgery (MBBS), The University of Hong Kong
-
Diploma in Practical Dermatology, University of Wales College of Medicine, UK
-
Fellow, Royal Australasian College of Surgeons
-
Fellow, Royal College of Surgeons of Edinburgh, UK
-
Fellow, Hong Kong College of Surgeons
-
Fellow, Hong Kong Academy of Medicine (Surgery)
According to a 2009 analysis by the National Cancer Institute (NCI), Wilms' tumor 1 (WT-1) is one of the best tumor antigens, highly expressed in various solid tumors and leukemias.
The cancer vaccine provided by Dr. Choi Tat Fai is a broad-spectrum and highly effective anti-cancer vaccine that can effectively prevent and treat up to 95% of cancer cell mutations. After administering the WT-1 vaccine, a special adjuvant within it slowly releases, inducing dendritic cells (DCs) to phagocytize the peptides in the vaccine, presenting antigens, and thereby increasing or inducing the immune system to produce memory T cells that can specifically recognize cancer cells. This achieves the goal of effective cancer prevention or even lifelong immunity against cancer.
Research by the National Cancer Institute has analyzed 75 malignant tumor antigens, comparing the ideal cancer antigen standards, including therapeutic functionality, immunogenicity (ability to elicit an immune response), specificity, and oncogenicity. The study ultimately found WT-1 to be the best tumor antigen.
